Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Buy” by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $11.67.

ACRS has been the subject of a number of recent research reports. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. HC Wainwright raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an “overweight” rating for the company. Finally, Scotiabank initiated coverage on shares of Aclaris Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock.

Institutional Trading of Aclaris Therapeutics

Large investors have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. increased its stake in shares of Aclaris Therapeutics by 253.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 29,200 shares during the last quarter. Alpine Global Management LLC bought a new position in Aclaris Therapeutics during the fourth quarter worth about $38,000. Velan Capital Investment Management LP acquired a new position in Aclaris Therapeutics during the fourth quarter worth approximately $67,000. Squarepoint Ops LLC raised its stake in Aclaris Therapeutics by 108.3% in the fourth quarter. Squarepoint Ops LLC now owns 292,892 shares of the biotechnology company’s stock valued at $726,000 after buying an additional 152,312 shares during the period. Finally, Man Group plc bought a new stake in Aclaris Therapeutics in the fourth quarter valued at approximately $133,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

ACRS stock opened at $1.54 on Friday. The stock has a market capitalization of $166.20 million, a P/E ratio of -2.96 and a beta of 0.53. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The business has a 50-day moving average of $2.01 and a 200-day moving average of $2.24.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.